modafinil
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Substance Dependence
Conditions
Substance Dependence, Amphetamine Dependence
Trial Timeline
Dec 1, 2009 → Jun 1, 2011
NCT ID
NCT00630097About modafinil
modafinil is a phase 2 stage product being developed by Pacific Biosciences for Substance Dependence. The current trial status is unknown. This product is registered under clinical trial identifier NCT00630097. Target conditions include Substance Dependence, Amphetamine Dependence.
What happened to similar drugs?
1 of 1 similar drugs in Substance Dependence were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01354470 | Phase 2 | Completed |
| NCT00630097 | Phase 2 | UNKNOWN |
| NCT00538655 | Phase 2 | Completed |
Competing Products
5 competing products in Substance Dependence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2 | 35 |
| Tapentadol IR + Oxycodone IR | Johnson & Johnson | Pre-clinical | 26 |
| Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] | Gilead Sciences | Pre-clinical | 22 |
| RDC-0313 + Buprenorphine + Placebo | Alkermes | Phase 1 | 26 |
| naltrexone for extended release injectable suspension | Alkermes | Approved | 40 |